Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 113

1.

CDK 4/6 inhibitors and stereotactic radiation in the management of hormone receptor positive breast cancer brain metastases.

Figura NB, Potluri TK, Mohammadi H, Oliver DE, Arrington JA, Robinson TJ, Etame AB, Tran ND, Liu JK, Soliman H, Forsyth PA, Sahebjam S, Yu HM, Han HS, Ahmed KA.

J Neurooncol. 2019 Sep;144(3):583-589. doi: 10.1007/s11060-019-03260-6. Epub 2019 Aug 9.

PMID:
31399935
2.

Breast leptomeningeal disease: a review of current practices and updates on management.

Figura NB, Rizk VT, Armaghani AJ, Arrington JA, Etame AB, Han HS, Czerniecki BJ, Forsyth PA, Ahmed KA.

Breast Cancer Res Treat. 2019 Sep;177(2):277-294. doi: 10.1007/s10549-019-05317-6. Epub 2019 Jun 17. Review.

PMID:
31209686
3.

Clinical outcomes of breast leptomeningeal disease treated with intrathecal trastuzumab, intrathecal chemotherapy, or whole brain radiation therapy.

Figura NB, Rizk VT, Mohammadi H, Evernden B, Mokhtari S, Yu HM, Robinson TJ, Etame AB, Tran ND, Liu J, Washington I, Diaz R, Czerniecki BJ, Soliman H, Han HS, Sahebjam S, Forsyth PA, Ahmed KA.

Breast Cancer Res Treat. 2019 Jun;175(3):781-788. doi: 10.1007/s10549-019-05170-7. Epub 2019 Mar 11.

PMID:
30859348
4.

Melanoma central nervous system metastases: An update to approaches, challenges, and opportunities.

Eroglu Z, Holmen SL, Chen Q, Khushalani NI, Amaravadi R, Thomas R, Ahmed KA, Tawbi H, Chandra S, Markowitz J, Smalley I, Liu JKC, Chen YA, Najjar YG, Karreth FA, Abate-Daga D, Glitza IC, Sosman JA, Sondak VK, Bosenberg M, Herlyn M, Atkins MB, Kluger H, Margolin K, Forsyth PA, Davies MA, Smalley KSM.

Pigment Cell Melanoma Res. 2019 May;32(3):458-469. doi: 10.1111/pcmr.12771. Epub 2019 Feb 19.

PMID:
30712316
5.

Combined Nivolumab and Ipilimumab in Melanoma Metastatic to the Brain.

Tawbi HA, Forsyth PA, Algazi A, Hamid O, Hodi FS, Moschos SJ, Khushalani NI, Lewis K, Lao CD, Postow MA, Atkins MB, Ernstoff MS, Reardon DA, Puzanov I, Kudchadkar RR, Thomas RP, Tarhini A, Pavlick AC, Jiang J, Avila A, Demelo S, Margolin K.

N Engl J Med. 2018 Aug 23;379(8):722-730. doi: 10.1056/NEJMoa1805453.

6.

Publisher Correction: Smac mimetics synergize with immune checkpoint inhibitors to promote tumour immunity against glioblastoma.

Beug ST, Beauregard CE, Healy C, Sanda T, St-Jean M, Chabot J, Walker DE, Mohan A, Earl N, Lun X, Senger DL, Robbins SM, Staeheli P, Forsyth PA, Alain T, LaCasse EC, Korneluk RG.

Nat Commun. 2018 Jul 18;9:16231. doi: 10.1038/ncomms16231.

7.

Viral Therapy Gets Personal: A Potential Gene Signature to Predict Susceptibility to Measles Virus Oncolysis.

Forsyth PA, Abate-Daga D.

J Natl Cancer Inst. 2018 Oct 1;110(10):1139-1140. doi: 10.1093/jnci/djy061. No abstract available.

PMID:
29757401
8.

Reply to Improving the survival of patients with American Joint Committee on Cancer stage III and IV melanoma.

Sloot S, Chen YA, Zhao X, Weber JL, Benedict JJ, Mulé JJ, Smalley KS, Weber JS, Zager JS, Forsyth PA, Sondak VK, Gibney GT.

Cancer. 2018 May 15;124(10):2254-2255. doi: 10.1002/cncr.31261. Epub 2018 Mar 15. No abstract available.

9.

Oncolytic Virotherapy for Malignant Gliomas.

Forsyth PA, Abate-Daga D.

J Clin Oncol. 2018 May 10;36(14):1440-1442. doi: 10.1200/JCO.2017.77.3192. Epub 2018 Feb 13. No abstract available.

PMID:
29437534
10.

Intrathecal trastuzumab in the management of HER2+ breast leptomeningeal disease: a single institution experience.

Figura NB, Long W, Yu M, Robinson TJ, Mokhtari S, Etame AB, Tran ND, Diaz R, Soliman H, Han HS, Sahebjam S, Forsyth PA, Ahmed KA.

Breast Cancer Res Treat. 2018 Jun;169(2):391-396. doi: 10.1007/s10549-018-4684-3. Epub 2018 Feb 1.

PMID:
29392582
11.

The biology and therapeutic management of melanoma brain metastases.

Abate-Daga D, Ramello MC, Smalley I, Forsyth PA, Smalley KSM.

Biochem Pharmacol. 2018 Jul;153:35-45. doi: 10.1016/j.bcp.2017.12.019. Epub 2017 Dec 24. Review.

12.

The Blood Brain Barrier and BRAF inhibitors: Implications for patients with melanoma brain metastases.

Smalley KSM, Forsyth PA.

Pharmacol Res. 2018 Sep;135:265-267. doi: 10.1016/j.phrs.2017.11.013. Epub 2017 Nov 13. No abstract available.

PMID:
29146209
13.

Improved survival of patients with melanoma brain metastases in the era of targeted BRAF and immune checkpoint therapies.

Sloot S, Chen YA, Zhao X, Weber JL, Benedict JJ, Mulé JJ, Smalley KS, Weber JS, Zager JS, Forsyth PA, Sondak VK, Gibney GT.

Cancer. 2018 Jan 15;124(2):297-305. doi: 10.1002/cncr.30946. Epub 2017 Oct 12.

14.

BRAF-MEK inhibition in melanoma brain metastases: a new hope.

Forsyth PA, Smalley KSM, Sondak VK.

Lancet Oncol. 2017 Jul;18(7):836-837. doi: 10.1016/S1470-2045(17)30449-7. No abstract available.

PMID:
28677560
15.

Erratum to: Older age at the completion of linear growth is associated with an increased risk of adult glioma.

Little RB, Burt Nabors L, Olson JJ, Thompson ZJ, Rozmeski CM, LaRocca RV, Forsyth PA, Thompson RC, Oster RA, Chowdhary SA, Egan KM.

Cancer Causes Control. 2017 Jul;28(7):717-718. doi: 10.1007/s10552-017-0893-z. No abstract available.

PMID:
28455551
16.

Clinical outcomes from maximum-safe resection of primary and metastatic brain tumors using awake craniotomy.

Groshev A, Padalia D, Patel S, Garcia-Getting R, Sahebjam S, Forsyth PA, Vrionis FD, Etame AB.

Clin Neurol Neurosurg. 2017 Jun;157:25-30. doi: 10.1016/j.clineuro.2017.03.017. Epub 2017 Mar 20.

PMID:
28384595
17.

Older age at the completion of linear growth is associated with an increased risk of adult glioma.

Little RB, Nabors LB, Olson JJ, Thompson ZJ, Rozmeski CM, LaRocca RV, Forsyth PA, Thompson RC, Oster RA, Chowdhary SA, Egan KM.

Cancer Causes Control. 2017 Jul;28(7):709-716. doi: 10.1007/s10552-017-0871-5. Epub 2017 Mar 4. Erratum in: Cancer Causes Control. 2017 Jul;28(7):717-718.

18.

Smac mimetics synergize with immune checkpoint inhibitors to promote tumour immunity against glioblastoma.

Beug ST, Beauregard CE, Healy C, Sanda T, St-Jean M, Chabot J, Walker DE, Mohan A, Earl N, Lun X, Senger DL, Robbins SM, Staeheli P, Forsyth PA, Alain T, LaCasse EC, Korneluk RG.

Nat Commun. 2017 Feb 15;8. doi: 10.1038/ncomms14278. Erratum in: Nat Commun. 2018 Jul 18;9:16231.

19.

Experimental Treatments for Leptomeningeal Metastases From Solid Malignancies.

Sahebjam S, Forsyth PA, Smalley KS, Tran ND.

Cancer Control. 2017 Jan;24(1):42-46. Review.

PMID:
28178711
20.

Clinical outcomes of melanoma brain metastases treated with stereotactic radiosurgery and anti-PD-1 therapy, anti-CTLA-4 therapy, BRAF/MEK inhibitors, BRAF inhibitor, or conventional chemotherapy.

Ahmed KA, Abuodeh YA, Echevarria MI, Arrington JA, Stallworth DG, Hogue C, Naghavi AO, Kim S, Kim Y, Patel BG, Sarangkasiri S, Johnstone PA, Sahebjam S, Khushalani NI, Forsyth PA, Harrison LB, Yu M, Etame AB, Caudell JJ.

Ann Oncol. 2016 Dec;27(12):2288-2294. doi: 10.1093/annonc/mdw417. Epub 2016 Sep 15.

PMID:
27637745
21.

A rare case of leptomeningeal carcinomatosis in a patient with uveal melanoma: case report and review of literature.

Fedorenko IV, Evernden B, Kenchappa RS, Sahebjam S, Ryzhova E, Puskas J, McIntosh L, Caceres G, Magliocco A, Etame A, Harbour JW, Smalley KS, Forsyth PA.

Melanoma Res. 2016 Oct;26(5):481-6. doi: 10.1097/CMR.0000000000000274. Review.

22.

Managing leptomeningeal melanoma metastases in the era of immune and targeted therapy.

Smalley KS, Fedorenko IV, Kenchappa RS, Sahebjam S, Forsyth PA.

Int J Cancer. 2016 Sep 15;139(6):1195-201. doi: 10.1002/ijc.30147. Epub 2016 Apr 30. Review.

23.

M011L-deficient oncolytic myxoma virus induces apoptosis in brain tumor-initiating cells and enhances survival in a novel immunocompetent mouse model of glioblastoma.

Pisklakova A, McKenzie B, Zemp F, Lun X, Kenchappa RS, Etame AB, Rahman MM, Reilly K, Pilon-Thomas S, McFadden G, Kurz E, Forsyth PA.

Neuro Oncol. 2016 Mar 8. pii: now006. [Epub ahead of print]

24.

Analgesic use and the risk of primary adult brain tumor.

Egan KM, Nabors LB, Thompson ZJ, Rozmeski CM, Anic GA, Olson JJ, LaRocca RV, Chowdhary SA, Forsyth PA, Thompson RC.

Eur J Epidemiol. 2016 Sep;31(9):917-25. doi: 10.1007/s10654-016-0129-7. Epub 2016 Feb 19.

25.

BIRC3 is a novel driver of therapeutic resistance in Glioblastoma.

Wang D, Berglund A, Kenchappa RS, Forsyth PA, Mulé JJ, Etame AB.

Sci Rep. 2016 Feb 18;6:21710. doi: 10.1038/srep21710.

26.

In vitro screen of a small molecule inhibitor drug library identifies multiple compounds that synergize with oncolytic myxoma virus against human brain tumor-initiating cells.

McKenzie BA, Zemp FJ, Pisklakova A, Narendran A, McFadden G, Lun X, Kenchappa RS, Kurz EU, Forsyth PA.

Neuro Oncol. 2015 Aug;17(8):1086-94. doi: 10.1093/neuonc/nou359. Epub 2015 Jan 20.

27.

Neurotrophin signaling via TrkB and TrkC receptors promotes the growth of brain tumor-initiating cells.

Lawn S, Krishna N, Pisklakova A, Qu X, Fenstermacher DA, Fournier M, Vrionis FD, Tran N, Chan JA, Kenchappa RS, Forsyth PA.

J Biol Chem. 2015 Feb 6;290(6):3814-24. doi: 10.1074/jbc.M114.599373. Epub 2014 Dec 23.

28.

LINAC-based stereotactic radiosurgery to the brain with concurrent vemurafenib for melanoma metastases.

Ahmed KA, Freilich JM, Sloot S, Figura N, Gibney GT, Weber JS, Sarangkasiri S, Chinnaiyan P, Forsyth PA, Etame AB, Rao NG.

J Neurooncol. 2015 Mar;122(1):121-6. doi: 10.1007/s11060-014-1685-x. Epub 2014 Dec 18.

PMID:
25519302
29.

Cellular factors promoting resistance to effective treatment of glioma with oncolytic myxoma virus.

Zemp FJ, McKenzie BA, Lun X, Reilly KM, McFadden G, Yong VW, Forsyth PA.

Cancer Res. 2014 Dec 15;74(24):7260-73. doi: 10.1158/0008-5472.CAN-14-0876. Epub 2014 Oct 21.

30.

Reproductive factors and risk of primary brain tumors in women.

Anic GM, Madden MH, Nabors LB, Olson JJ, LaRocca RV, Thompson ZJ, Pamnani SJ, Forsyth PA, Thompson RC, Egan KM.

J Neurooncol. 2014 Jun;118(2):297-304. doi: 10.1007/s11060-014-1427-0. Epub 2014 Apr 4.

31.

p75 neurotrophin receptor cleavage by α- and γ-secretases is required for neurotrophin-mediated proliferation of brain tumor-initiating cells.

Forsyth PA, Krishna N, Lawn S, Valadez JG, Qu X, Fenstermacher DA, Fournier M, Potthast L, Chinnaiyan P, Gibney GT, Zeinieh M, Barker PA, Carter BD, Cooper MK, Kenchappa RS.

J Biol Chem. 2014 Mar 21;289(12):8067-85. doi: 10.1074/jbc.M113.513762. Epub 2014 Feb 11.

32.

Novel treatments for melanoma brain metastases.

Kenchappa RS, Tran N, Rao NG, Smalley KS, Gibney GT, Sondak VK, Forsyth PA.

Cancer Control. 2013 Oct;20(4):298-306. Review.

PMID:
24077406
33.

Toenail iron, genetic determinants of iron status, and the risk of glioma.

Anic GM, Madden MH, Thompson RC, Nabors LB, Olson JJ, Larocca RV, Browning JE, Brockman JD, Forsyth PA, Egan KM.

Cancer Causes Control. 2013 Dec;24(12):2051-8. doi: 10.1007/s10552-013-0281-2. Epub 2013 Aug 31.

34.

Myxoma virus infection promotes NK lysis of malignant gliomas in vitro and in vivo.

Ogbomo H, Zemp FJ, Lun X, Zhang J, Stack D, Rahman MM, McFadden G, Mody CH, Forsyth PA.

PLoS One. 2013 Jun 10;8(6):e66825. doi: 10.1371/journal.pone.0066825. Print 2013.

35.

Resistance to oncolytic myxoma virus therapy in nf1(-/-)/trp53(-/-) syngeneic mouse glioma models is independent of anti-viral type-I interferon.

Zemp FJ, McKenzie BA, Lun X, Maxwell L, Reilly KM, McFadden G, Yong VW, Forsyth PA.

PLoS One. 2013 Jun 6;8(6):e65801. doi: 10.1371/journal.pone.0065801. Print 2013. Erratum in: PLoS One. 2014;9(6):e101827.

36.

Treating brain tumor-initiating cells using a combination of myxoma virus and rapamycin.

Zemp FJ, Lun X, McKenzie BA, Zhou H, Maxwell L, Sun B, Kelly JJ, Stechishin O, Luchman A, Weiss S, Cairncross JG, Hamilton MG, Rabinovich BA, Rahman MM, Mohamed MR, Smallwood S, Senger DL, Bell J, McFadden G, Forsyth PA.

Neuro Oncol. 2013 Jul;15(7):904-20. doi: 10.1093/neuonc/not035. Epub 2013 Apr 12.

37.

Neutrophils recruited to sites of infection protect from virus challenge by releasing neutrophil extracellular traps.

Jenne CN, Wong CH, Zemp FJ, McDonald B, Rahman MM, Forsyth PA, McFadden G, Kubes P.

Cell Host Microbe. 2013 Feb 13;13(2):169-80. doi: 10.1016/j.chom.2013.01.005.

38.

REO-001: A phase I trial of percutaneous intralesional administration of reovirus type 3 dearing (Reolysin®) in patients with advanced solid tumors.

Morris DG, Feng X, DiFrancesco LM, Fonseca K, Forsyth PA, Paterson AH, Coffey MC, Thompson B.

Invest New Drugs. 2013 Jun;31(3):696-706. doi: 10.1007/s10637-012-9865-z. Epub 2012 Aug 12.

PMID:
22886613
39.

An exploratory analysis of common genetic variants in the vitamin D pathway including genome-wide associated variants in relation to glioma risk and outcome.

Anic GM, Thompson RC, Nabors LB, Olson JJ, Browning JE, Madden MH, Murtagh FR, Forsyth PA, Egan KM.

Cancer Causes Control. 2012 Sep;23(9):1443-9. doi: 10.1007/s10552-012-0018-7. Epub 2012 Jun 28. Erratum in: Cancer Causes Control. 2012 Oct;23(10):1745. Burton Nabors, L [corrected to Nabors, L Burton]; Reed Murtagh, F [corrected to Murtagh, F Reed].

40.

Melanoma in the brain: biology and therapeutic options.

Gibney GT, Forsyth PA, Sondak VK.

Melanoma Res. 2012 Jun;22(3):177-83. doi: 10.1097/CMR.0b013e328352dbef. Review.

PMID:
22495668
41.

Immunotherapy in gliomas: limitations and potential of natural killer (NK) cell therapy.

Ogbomo H, Cinatl J Jr, Mody CH, Forsyth PA.

Trends Mol Med. 2011 Aug;17(8):433-41. doi: 10.1016/j.molmed.2011.03.004. Epub 2011 Apr 19. Review.

PMID:
21507717
42.

A phase 1/2 study of orally administered synthetic hypericin for treatment of recurrent malignant gliomas.

Couldwell WT, Surnock AA, Tobia AJ, Cabana BE, Stillerman CB, Forsyth PA, Appley AJ, Spence AM, Hinton DR, Chen TC.

Cancer. 2011 Nov 1;117(21):4905-15. doi: 10.1002/cncr.26123. Epub 2011 Mar 31.

43.

Leptomeningeal disease in oligodendroglial tumors: a population-based study.

Roldán G, Chan J, Eliasziw M, Cairncross JG, Forsyth PA.

J Neurooncol. 2011 Sep;104(3):811-5. doi: 10.1007/s11060-011-0551-3. Epub 2011 Mar 4.

44.

Attenuated reovirus displays oncolysis with reduced host toxicity.

Kim M, Garant KA, zur Nieden NI, Alain T, Loken SD, Urbanski SJ, Forsyth PA, Rancourt DE, Lee PW, Johnston RN.

Br J Cancer. 2011 Jan 18;104(2):290-9. doi: 10.1038/sj.bjc.6606053. Epub 2010 Dec 21.

45.

Public goods games with reward in finite populations.

Forsyth PA, Hauert C.

J Math Biol. 2011 Jul;63(1):109-23. doi: 10.1007/s00285-010-0363-7. Epub 2010 Sep 24.

PMID:
20865261
46.

Efficacy and safety/toxicity study of recombinant vaccinia virus JX-594 in two immunocompetent animal models of glioma.

Lun X, Chan J, Zhou H, Sun B, Kelly JJ, Stechishin OO, Bell JC, Parato K, Hu K, Vaillant D, Wang J, Liu TC, Breitbach C, Kirn D, Senger DL, Forsyth PA.

Mol Ther. 2010 Nov;18(11):1927-36. doi: 10.1038/mt.2010.183. Epub 2010 Aug 31.

47.

Oncolytic viruses as experimental treatments for malignant gliomas: using a scourge to treat a devil.

Zemp FJ, Corredor JC, Lun X, Muruve DA, Forsyth PA.

Cytokine Growth Factor Rev. 2010 Apr-Jun;21(2-3):103-17. doi: 10.1016/j.cytogfr.2010.04.001. Epub 2010 May 18. Review.

PMID:
20483653
48.

Normal human monocytes exposed to glioma cells acquire myeloid-derived suppressor cell-like properties.

Rodrigues JC, Gonzalez GC, Zhang L, Ibrahim G, Kelly JJ, Gustafson MP, Lin Y, Dietz AB, Forsyth PA, Yong VW, Parney IF.

Neuro Oncol. 2010 Apr;12(4):351-65. doi: 10.1093/neuonc/nop023. Epub 2009 Dec 22.

49.

Oncolytic viral therapy for prostate cancer: efficacy of reovirus as a biological therapeutic.

Thirukkumaran CM, Nodwell MJ, Hirasawa K, Shi ZQ, Diaz R, Luider J, Johnston RN, Forsyth PA, Magliocco AM, Lee P, Nishikawa S, Donnelly B, Coffey M, Trpkov K, Fonseca K, Spurrell J, Morris DG.

Cancer Res. 2010 Mar 15;70(6):2435-44. doi: 10.1158/0008-5472.CAN-09-2408. Epub 2010 Mar 9.

50.

Vesicular stomatitis virus oncolysis is potentiated by impairing mTORC1-dependent type I IFN production.

Alain T, Lun X, Martineau Y, Sean P, Pulendran B, Petroulakis E, Zemp FJ, Lemay CG, Roy D, Bell JC, Thomas G, Kozma SC, Forsyth PA, Costa-Mattioli M, Sonenberg N.

Proc Natl Acad Sci U S A. 2010 Jan 26;107(4):1576-81. doi: 10.1073/pnas.0912344107. Epub 2010 Jan 4.

Supplemental Content

Loading ...
Support Center